Engineered immune cells take aim at Hard-to-Treat solid tumors
NCT ID NCT07266311
First seen Jan 04, 2026 · Last updated May 24, 2026 · Updated 24 times
Summary
This early-phase trial tests whether a patient's own immune cells, modified to target the CLDN18.2 protein, can safely shrink advanced solid tumors. About 18 adults whose cancer has not responded to standard treatments will receive a single infusion of these CAR T-cells. The study focuses on side effects and whether tumors shrink or stop growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLAUDIN18.2 POSITIVE ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The General Hospital of Western Theater Command
Chengdu, Sichuan, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.